Humacyte (NASDAQ:HUMA – Get Free Report) released its quarterly earnings results on Wednesday. The company reported ($0.16) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.10) by ($0.06), FiscalAI reports. The firm had revenue of $0.41 million for the quarter, compared to analyst estimates of $1.12 million. Humacyte had a negative return on equity of 2,914.18% and a negative net margin of 4,836.06%.
Here are the key takeaways from Humacyte’s conference call:
- V012 Phase III interim results exceeded expectations in female dialysis patients: ATEV recipients had 91 more catheter-free days than AV fistula patients, with significantly fewer infections. Humacyte plans to file a supplemental BLA in November 2026 and is targeting a potential launch in late Q2 2027 if priority review is granted.
- Humacyte is rebuilding its SYMVESS commercial organization with vascular-surgery-focused sales personnel, a national accounts strategy, streamlined hospital value-analysis processes, and introductory pricing. At least 20 major U.S. healthcare systems are reportedly in the process of adopting the product, although meaningful benefits are expected mainly in the second half of 2026.
- The FDA accepted Humacyte’s IND for its smaller-diameter CTEV vessel in coronary artery bypass grafting, and the company expects to begin a 10-patient Phase IIa study during the current quarter. Management said initial CTEV manufacturing will not materially constrain ATEV commercial production.
- Financial results continued to reflect commercialization and manufacturing costs: second-quarter revenue was only $0.4 million, cost of goods sold reached $1.2 million including a $0.7 million inventory reserve, and net loss was $36.8 million. Cash, cash equivalents, and restricted cash totaled $80.3 million at June 30, 2026, supported in part by equity-sale proceeds.
Humacyte Stock Down 11.3%
NASDAQ:HUMA traded down $0.08 on Wednesday, reaching $0.63. The stock had a trading volume of 6,773,800 shares, compared to its average volume of 7,854,669. The company has a 50-day moving average of $0.82 and a 200 day moving average of $0.91. The company has a current ratio of 3.93, a quick ratio of 3.32 and a debt-to-equity ratio of 5.46. The stock has a market cap of $139.89 million, a P/E ratio of -1.11 and a beta of 2.53. Humacyte has a 12-month low of $0.55 and a 12-month high of $2.55.
Analyst Ratings Changes
Check Out Our Latest Stock Report on Humacyte
Insider Transactions at Humacyte
In other Humacyte news, Director Kathleen Sebelius acquired 56,818 shares of the stock in a transaction on Tuesday, May 19th. The stock was purchased at an average price of $0.88 per share, for a total transaction of $49,999.84. Following the purchase, the director directly owned 148,025 shares in the company, valued at $130,262. This trade represents a 62.30% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, insider Shamik J. Parikh sold 45,887 shares of Humacyte stock in a transaction that occurred on Monday, May 18th. The stock was sold at an average price of $0.90, for a total value of $41,298.30. Following the sale, the insider owned 272,713 shares in the company, valued at $245,441.70. This represents a 14.40% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Corporate insiders own 3.10% of the company’s stock.
Institutional Trading of Humacyte
A number of institutional investors and hedge funds have recently modified their holdings of the business. Virtu Financial LLC acquired a new position in shares of Humacyte in the 4th quarter valued at about $252,000. XTX Topco Ltd boosted its stake in Humacyte by 236.1% in the fourth quarter. XTX Topco Ltd now owns 650,858 shares of the company’s stock valued at $625,000 after acquiring an additional 457,236 shares during the period. Quadrature Capital Ltd bought a new position in Humacyte during the 4th quarter worth $201,000. Millennium Management LLC grew its position in shares of Humacyte by 129.5% during the fourth quarter. Millennium Management LLC now owns 2,631,990 shares of the company’s stock worth $2,528,000 after acquiring an additional 1,485,152 shares during the last quarter. Finally, Engineers Gate Manager LP acquired a new stake in shares of Humacyte in the 4th quarter worth about $82,000. 44.71% of the stock is owned by institutional investors and hedge funds.
About Humacyte
Humacyte, Inc is a clinical-stage biotechnology company focused on the development and manufacturing of off-the-shelf, regenerative human acellular vessels (HAVs) designed to address critical vascular access needs. The company’s proprietary vessels are engineered from human donor cells and then decellularized to create a biocompatible scaffold capable of integrating with a patient’s own tissue. Humacyte’s primary business activities encompass process development, large-scale manufacturing, and clinical evaluation of HAVs for use in end-stage renal disease, peripheral arterial disease and other vascular repair applications.
The company’s lead product candidate, the HAV, has advanced through multiple clinical trials for arteriovenous access in hemodialysis patients, demonstrating durability, reduced infection rates and compatibility with repeated cannulation.
Read More
- Five stocks we like better than Humacyte
- Visa’s AI Opportunity Is Hiding in Every Transaction
- On Holding’s Price Stumble May Be an Opening for a Company Built to Run
- TSMC’s 44.7% Sales Surge Signals the AI Boom Is Still Alive
- CoreWeave’s $129 Billion AI Backlog Changes the Bull Case
Receive News & Ratings for Humacyte Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Humacyte and related companies with MarketBeat.com's FREE daily email newsletter.
-inc-logo-1200x675.jpg){kind=logo}
